This result is not in line with most studies performed in other cancers, where ANXA1 upregulation was involved in mechanisms of chemoresistance, such as in triple-negative breast cancer cell line BT-549 [59], in oxaliplatin-resistant gastric cancer cells [60], and in the cisplatin-resistant A549 lung adenocarcinoma cell line [61]. The gene discussed is ANXA1; the disease is cancer.